Enhanced Immunogenicity of CD4(+) T-cell Responses and Protective Efficacy of a DNA-modified Vaccinia Virus Ankara Prime-boost Vaccination Regimen for Murine Tuberculosis

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2001 Feb 13

PMID 11159955

Citations 80

Authors

H McShane

R Brookes

S C Gilbert

A V Hill

Affiliations

Soon will be listed here.

Abstract

DNA vaccines whose DNA encodes a variety of antigens from Mycobacterium tuberculosis have been evaluated for immunogenicity and protective efficacy. CD8(+) T-cell responses and protection achieved in other infectious disease models have been optimized by using a DNA immunization to prime the immune system and a recombinant virus encoding the same antigen(s) to boost the response. A DNA vaccine (D) and recombinant modified vaccinia virus Ankara (M) in which the DNA encodes early secreted antigenic target 6 and mycobacterial protein tuberculosis 63 synthesized, and each was found to generate specific gamma interferon (IFN-gamma)-secreting CD4(+) T cells. Enhanced CD4(+) IFN-gamma T-cell responses were produced by both D-M and M-D immunization regimens. Significantly higher levels of IFN-gamma were seen with a D-D-D-M immunization regimen. The most immunogenic regimens were assessed in a challenge study and found to produce protection equivalent to that produced by Mycobacterium bovis BCG. Thus, heterologous prime-boost regimens boost CD4(+) as well as CD8(+) T-cell responses, and the use of heterologous constructs encoding the same antigen(s) may improve the immunogenicity and protective efficacy of DNA vaccines against tuberculosis and other diseases.

Citing Articles

Immune correlates of protection as a game changer in tuberculosis vaccine development.

Wang J, Fan X, Hu Z NPJ Vaccines. 2024; 9(1):208.

PMID: 39478007 PMC: 11526030. DOI: 10.1038/s41541-024-01004-w.

DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies.

Kazakova A, Zhelnov P, Sidorov R, Rogova A, Vasileva O, Ivanov R Front Immunol. 2024; 15:1457327.

PMID: 39421744 PMC: 11483866. DOI: 10.3389/fimmu.2024.1457327.

Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing.

Bhattacharya S, Jenkins M, Keshavarz-Joud P, Bourque A, White K, Alvarez Barkane A ACS Nano. 2024; .

PMID: 39041587 PMC: 11308774. DOI: 10.1021/acsnano.4c00949.

Viral-vectored boosting of OmcB- or CPAF-specific T-cell responses fail to enhance protection from Chlamydia muridarum in infection-immune mice and elicits a non-protective CD8-dominant response in naïve mice.

Poston T, Girardi J, Polson A, Bhardwaj A, Yount K, Jaras Salas I Mucosal Immunol. 2024; 17(5):1005-1018.

PMID: 38969067 PMC: 11495396. DOI: 10.1016/j.mucimm.2024.06.012.

Bacillus Calmette-Guérin (BCG)-Induced Protection in Brain Disorders.

Mathias K, Machado R, Stork S, Martins C, Kursancew A, de Rezende V Inflammation. 2024; 47(6):1902-1917.

PMID: 38664351 DOI: 10.1007/s10753-024-02018-1.

References

Huygen K, Content J, Denis O, Montgomery D, Yawman A, Deck R . Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med. 1996; 2(8):893-8. DOI: 10.1038/nm0896-893. View

Schneider J, Gilbert S, Hannan C, Degano P, Prieur E, Sheu E . Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev. 1999; 170:29-38. DOI: 10.1111/j.1600-065x.1999.tb01326.x. View

Brandt L, Oettinger T, Holm A, Andersen A, Andersen P . Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol. 1996; 157(8):3527-33. View

Fine P, Rodrigues L . Modern vaccines. Mycobacterial diseases. Lancet. 1990; 335(8696):1016-20. DOI: 10.1016/0140-6736(90)91074-k. View

Schneider J, Gilbert S, Blanchard T, Hanke T, Robson K, Hannan C . Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med. 1998; 4(4):397-402. DOI: 10.1038/nm0498-397. View

Flynn J, GOLDSTEIN M, Triebold K, Koller B, Bloom B . Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A. 1992; 89(24):12013-7. PMC: 50688. DOI: 10.1073/pnas.89.24.12013. View

Zhu X, Venkataprasad N, Thangaraj H, Hill M, Singh M, Ivanyi J . Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. J Immunol. 1997; 158(12):5921-6. View

Sedegah M, Jones T, Kaur M, Hedstrom R, Hobart P, Tine J . Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A. 1998; 95(13):7648-53. PMC: 22711. DOI: 10.1073/pnas.95.13.7648. View

Horwitz M, Lee B, DILLON B, Harth G . Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 1995; 92(5):1530-4. PMC: 42553. DOI: 10.1073/pnas.92.5.1530. View

10.

HARBOE M, Oettinger T, Wiker H, Rosenkrands I, Andersen P . Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun. 1996; 64(1):16-22. PMC: 173721. DOI: 10.1128/iai.64.1.16-22.1996. View

11.

Newport M, Huxley C, Huston S, Hawrylowicz C, Oostra B, Williamson R . A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996; 335(26):1941-9. DOI: 10.1056/NEJM199612263352602. View

12.

Stoute J, Slaoui M, Heppner D, Momin P, Kester K, Desmons P . A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997; 336(2):86-91. DOI: 10.1056/NEJM199701093360202. View

13.

Lalvani A, Brookes R, Hambleton S, Britton W, Hill A, McMichael A . Rapid effector function in CD8+ memory T cells. J Exp Med. 1997; 186(6):859-65. PMC: 2199056. DOI: 10.1084/jem.186.6.859. View

14.

Barnes P, Bloch A, Davidson P, Snider Jr D . Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1991; 324(23):1644-50. DOI: 10.1056/NEJM199106063242307. View

15.

Tascon R, Colston M, Ragno S, Stavropoulos E, Gregory D, Lowrie D . Vaccination against tuberculosis by DNA injection. Nat Med. 1996; 2(8):888-92. DOI: 10.1038/nm0896-888. View

16.

Blanchard T, Alcami A, Andrea P, Smith G . Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol. 1998; 79 ( Pt 5):1159-67. DOI: 10.1099/0022-1317-79-5-1159. View

17.

Tighe H, Corr M, Roman M, Raz E . Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today. 1998; 19(2):89-97. DOI: 10.1016/s0167-5699(97)01201-2. View

18.

Manca C, Lyashchenko K, Wiker H, Usai D, Colangeli R, Gennaro M . Molecular cloning, purification, and serological characterization of MPT63, a novel antigen secreted by Mycobacterium tuberculosis. Infect Immun. 1997; 65(1):16-23. PMC: 174551. DOI: 10.1128/iai.65.1.16-23.1997. View

19.

Lalvani A, Brookes R, Wilkinson R, Malin A, Pathan A, Andersen P . Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 1998; 95(1):270-5. PMC: 18198. DOI: 10.1073/pnas.95.1.270. View

20.

Orme I . Pillars Article: The Kinetics of Emergence and Loss of Mediator T Lymphocytes Acquired in Response to Infection with . . 1987. 138: 293-298. J Immunol. 2017; 199(3):833-838. View